Breast Cancer Clinical Trials in San Francisco

Showing 241-260 of 350 trials

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

NCT02358200

Open label, non-randomized, dose escalation and expansion Phase Ia/b trial to evaluate the safety of the combination of BMN 673 and carboplatin, and subsequently BMN 673 in combination with paclitaxel and carboplatin to determine the recommended Phase II dose of the combination.

Triple Negative Metastatic Breast CancerBRCA-mutated Solid Tumor

Pamela Munster23 participantsStarted Feb 2015

San Francisco, California, United States

COMPLETEDPhase 3< 1 mile

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

NCT00390455

This randomized phase III trial studies fulvestrant and lapatinib to see how well they work compared to fulvestrant and a placebo in treating postmenopausal women with stage III or stage IV breast cancer that is hormone receptor-positive. Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes. Lapatinib may stop the growth of breast cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether fulvestrant is more effective with or without lapatinib in treating breast cancer.

Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more

National Cancer Institute (NCI)295 participantsStarted Sep 2006

Little Rock, Arkansas, United States • Arroyo Grande, California, United States • Arroyo Grande, California, United States +365 more locations

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Breast Cancer Trials in Other Cities

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial

MRI to Detect Breast Tumors in Women

MRI for Detecting Cancer in Women Who Are at High Risk of Developing Breast Cancer

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer

Integrative Approaches For Cancer Survivorship 2: Project 1

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer

Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy

Vitamin D and Breast Cancer: Does Weight Make a Difference?

Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Other Conditions in San Francisco